BioMark - Cancer Research Services

• Screening for high risk group
• Precision medicine
• Assess high risk relapse population cohort
• Assess malignancy

Spermidine/spermine N-acetyltransferase 1 (SSAT 1) Gene Expression in Human Cancer

Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba

Status: Open

Spermidine/spermine N-acetyltransferase 1 (SSAT1) Gene Expression and Identification of High-Performance Metabolites in Human Cancer (Amended)

Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Co-Investigator: Dr. Daniel S. Sitar, Ph.D, University of Manitoba
Co-Investigator: Dr. Paramjit Tappia, Ph.D, Asper Clinical Research Institute

Status: Open

• CancerCare Manitoba ethics approval obtained for the protocol
• Patients to be recruited newly diagnosed and treated
• Utilize both SSAT1 and new panels
• Expand clinical trial sites in N. America

• Identified and validated several putative markers
• Expanding trial samples
• Incorporate other clinical and imaging data

• In discussion with a major European centre to develop a comprehensive Omics panel of markers for high relapse cancer cohort
• Modify protocol and potentially extend trial to additional North American sites after Health Canada and ethics approvals are granted.